Evercore ISI raised the firm’s price target on Quest Diagnostics (DGX) to $190 from $185 and keeps an In Line rating on the shares as the firm updates estimates and makes several tactical calls in the Healthcare Technology & Distribution group ahead of Q3 earnings season.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $190 from $185 at Barclays
- Guardant Health, Quest Diagnostics announce blood-based screening test pact
- Quest Diagnostics partners with Epic for streamlined laboratory testing
- Haystack Oncology, Rutgers Cancer Institute collaborate to study Haystack MRD
- Quest Diagnostics: Strong Growth Prospects and Operational Efficiency Justify Buy Rating